CDKN2A and melanoma: According to the mutational spectrum, the RAS-MAPK-AKT is the pathway most frequently (91%) activated in melanoma, followed by the RB1/CDKN2A cell-cycle pathway (69%) and MDM2A/TP53 (19%).